MONOCLONAL ANTIBODIES IN THE IMMUNOHISTOCHEMICAL CLASS

本研究项目的目的是筛选， 全面测试单克隆抗体（Mab）， 免疫组织化学，以确定那些能够 提高了组织学诊断的准确性，或者， 那些识别预后标志物的分子 意义 也从各种外部来源获得的Mab 在我们实验室生产的产品将被广泛筛选 针对一组正常人体组织和选定的肿瘤， 不同的组织发生和分化程度。 冷冻 我们冷冻肿瘤库中的肿瘤将作为“黄金法则” 用于石蜡包埋组织的比较研究。 别动- 干燥（未固定）组织、乙醇固定和福尔马林固定组织，所有 将用每种Mab检测石蜡包埋的组织。 各种 免疫组织化学方法将首先用于 冷冻和石蜡包埋组织，以最大限度地选择 每种抗原/抗体的最佳处理。 的抗体 经过严格的筛选显示组织或肿瘤的区别 将对更大的油井组进行产能测试 特征性肿瘤的适当类型取决于 筛选期间显示的特异性。 为了方便筛选， 生物学意义的标记的研究，特别是制备 含有肿瘤样品的多肿瘤块， 将使用临床定义的患者群体。 的结果 免疫组化研究将与 组织病理学诊断、肿瘤分级、疾病分期、缓解 治疗，生存和其他预后参数的具体 对所涉及的肿瘤的意义。

The purpose of this research project is to screen, and comprehensively test monoclonal antibodies (Mabs) by immunohistochemistry, in order to identify those capable of increasing the accuracy of histological diagnosis of, alternatively, those which recognize marker substances of prognostic significance. Mabs obtained from various external sources as well as produced in our own laboratory will be extensively screened against a panel of normal human tissues and selected neoplasms of variable histogenesis and degrees of differentiation. Frozen tumors from our frozen tumor bank will serve as the "golden rule" for comparative studies with paraffin embedded tissues. Freeze- dried (unfixed) tissue, ethanol-fixed and formalin-fixed tissues, all embedded in paraffin will be tested with each Mab. Various immunohistochemical methods will be initially employed on frozen and paraffin embedded tissues to maximize selection of the optimal handling for each antigen/antibody. Antibodies which after rigorous screening show tissue or tumor discriminatory capacity will be tested against a larger group of well characterized neoplasms of appropriate type depending on the specificity shown during screening. To facilitate screening in search of markers of biological significance, especially prepared multi-tumor blocks containing samples of neoplasms from clinically-defined patient populations will be used. The results of the immunohistochemical studies will be correlated with the histopathologic diagnosis, tumor grade, stage of disease, response to therapy, survival and other prognostic parameters of specific significance for the neoplasms involved.